USA flag logo/image

An Official Website of the United States Government

Size-Dependent Uptake of Tc(I)-Labeled RGD Analogs

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
75471
Program Year/Program:
2005 / STTR
Agency Tracking Number:
CA112797
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
MOLECULAR INSIGHT PHARMACEUTICALS, INC.
160 SECOND ST CAMBRIDGE, MA 02142-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2005
Title: Size-Dependent Uptake of Tc(I)-Labeled RGD Analogs
Agency: HHS
Contract: 1R41CA112797-01
Award Amount: $299,810.00
 

Abstract:

DESCRIPTION (provided by applicant): Anti-angiogenic therapy is currently one of the most active fields in cancer research. There are four basic approaches to limiting angiogenesis: blocking growth factors, inhibiting matrix proteases, directly targeting endothelial cells, and upregulating endogenous inhibitors. Although there is no simple answer to date for blocking angiogenesis, one approach now in clinical results is targeting integrin receptors (Vitaxin, EMD121974, & SB-265123 which target the alpha v, beta 3 integrin). Since the key biochemical parameter in angiogenesis has not been defined and is likely to be a different biochemical target in different tumor types, a molecular probe for the integrin receptor will be important in guiding the choice of patients for integrin receptor antagonist therapy. Five different molecular weight dextrans will be used to span the spectra of possible permeabilities. One set of dextrans will be labeled with both the RGD peptide and Tc-99m. The other set of dextrans will be labeled with RGE and Tc-99m and will serve as a control because changing the molecular weight of the dextran can result in "localization" that is heavily dependent on the permeability of the molecule rather than the specific binding of the RGD peptide to the integrin receptor. This control molecule will therefore serve as a reference for non-integrin receptor processes much like the "reference tissue" model is used in positron emission tomography (PET) neurochemistry imaging. In that case, a tissue that does not contain the target receptor is used as a reference whereas in this study, the dextran control without the RGD peptide will serve as the reference.

Principal Investigator:

David R. Vera
6195435330
DVERA@UCSD.EDU

Business Contact:


6174925554
Small Business Information at Submission:

Molecular Insight Pharmaceuticals, Inc.
Molecular Insight Pharmaceuticals, Inc. 160 Second St Cambridge, MA 02142

EIN/Tax ID: 040562086
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
UNIVERSITY OF CALIFORNIA SAN DIEGO
UNIVERSITY OF CALIFORNIA SAN DIEGO
9500 GILMAN DR, Dept. 0934
LA JOLLA, CA 92093
RI Type: Nonprofit college or university